Lazar David E. 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Aug 4, 2025
Insider Transaction Report
Form 4
Lazar David E.
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-07-30$12.36/sh−6,750$83,430→ 155,838 total
Footnotes (2)
- [F1]The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split").
- [F2]Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date.